Evidence map›Paper›PMID 42310339›Full record

ArticleScientific reports2026

Early cancer biomarker detection using a prism-based multi-resonant Ag/BaTiO₃/BP plasmonic sensor.

P Vimal Kumar, N Bhuvaneswary, N Thenmoezhi, M Jeya Sundari

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

P Vimal KumarDepartment of CSE, P.S.R. Engineering College, Sivakasi, Tamill Nadu, India. mevimal2016@gmail.com.ORCID http://orcid.org/0000-0003-4707-9978
N BhuvaneswaryDepartment of ECE, Kalasalingam Academy of Research and Education, Krishnankoil, 626126, Tamill Nadu, India.ORCID http://orcid.org/0000-0001-6400-6602
N ThenmoezhiDepartment of ECE, AAA College of Engineering and Technology, Sivakasi, 626005, Tamill Nadu, India.ORCID http://orcid.org/0000-0002-0073-4317
M Jeya SundariDepartment of Computer Science and Business Systems, Ramco Institute of Technology, Rajapalayam, Tamill Nadu, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early and precise detection of cancer biomarkers with a ultra low concentration is a critical issue in clinical diagnostics mainly because of limited sensitivity, low selectivity as well as variable workability of the conventional surface plasmon resonance (SPR) biosensors. In order to deal with these drawbacks, this paper suggests a new prism-based, multi-resonant SPR biosensor with an Ag/BaTiO3/Black Phosphorus (BP) heterostructure. The goal is to improve field confinement, responsive refractive index and multiplexing capability to detected cancer biomarkers at an early-stage. The transfer matrix method was used to model the biosensor design and this was confirmed by finite element-based electromagnetic finite element simulations. The main plasmonic coating is Silver, BaTiO3 is a high-permittivity dielectric spacer to stabilize field coupling and the anisotropic BP is the active sensing material. Results of the simulation show an angular sensitivity of 412.14°/RIU and a figure of merit (FOM) of 352.26 RIU

Indexed as

Barium CompoundsBiomarkers, TumorBiosensing TechniquesEarly Detection of CancerPhosphorusSilverSurface Plasmon ResonanceTitaniumHumansBarium Compoundsbarium titanate(IV)Biomarkers, TumorPhosphorusSilverTitaniumBarium Titanate (BaTiO₃)Black Phosphorus (BP)Cancer Biomarker DetectionMulti-Resonant Biosensor and Refractive Index Sensitivity.Surface Plasmon Resonance (SPR)

Identifiers

PMID42310339
PMCPMC13542278

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.